343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA
Reg. FD, Other Events
Director Departures - Margaret FitzPatrick and Dr. Joanne Curley Not Standing...
Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
FY 2025
Q3
Q2
Q1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence